Seizert Capital Partners LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 10.6% during the third quarter, HoldingsChannel.com reports. The firm owned 432,000 shares of the biopharmaceutical company’s stock after selling 51,300 shares during the quarter. Seizert Capital Partners LLC’s holdings in Pfizer were worth $15,422,000 as of its most recent filing with the SEC.
Other hedge funds have also recently modified their holdings of the company. Janus Henderson Group PLC raised its holdings in Pfizer by 243.5% in the 2nd quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock valued at $442,574,000 after acquiring an additional 9,339,749 shares during the period. Vanguard Group Inc. raised its holdings in Pfizer by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after acquiring an additional 9,239,499 shares during the period. Renaissance Technologies LLC bought a new position in Pfizer in the 2nd quarter valued at about $268,389,000. Canada Pension Plan Investment Board raised its holdings in Pfizer by 249.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock valued at $359,871,000 after acquiring an additional 7,649,416 shares during the period. Finally, Longview Partners Guernsey LTD raised its holdings in Pfizer by 32.0% in the 3rd quarter. Longview Partners Guernsey LTD now owns 24,369,672 shares of the biopharmaceutical company’s stock valued at $869,997,000 after acquiring an additional 5,901,100 shares during the period. 69.74% of the stock is currently owned by institutional investors.
Pfizer Inc. (PFE) opened at $36.56 on Friday. Pfizer Inc. has a 52-week low of $30.90 and a 52-week high of $37.35. The stock has a market cap of $217,920.00, a P/E ratio of 22.43, a price-to-earnings-growth ratio of 2.46 and a beta of 1.01. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be given a dividend of $0.34 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date is Thursday, February 1st. This represents a $1.36 annualized dividend and a dividend yield of 3.72%. Pfizer’s dividend payout ratio (DPR) is currently 78.53%.
Pfizer announced that its board has initiated a stock buyback program on Monday, December 18th that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock buyback programs are often a sign that the company’s management believes its stock is undervalued.
PFE has been the topic of several research analyst reports. BMO Capital Markets set a $37.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, October 10th. ValuEngine raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Deutsche Bank set a $38.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, October 11th. Finally, Morgan Stanley upgraded shares of Pfizer from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $35.00 to $39.00 in a research report on Wednesday, September 20th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $38.83.
In related news, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the sale, the executive vice president now owns 46,963 shares in the company, valued at approximately $1,740,918.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the sale, the insider now owns 103,458 shares in the company, valued at approximately $3,827,946. The disclosure for this sale can be found here. Insiders have sold a total of 29,450 shares of company stock worth $1,065,220 in the last quarter. 0.06% of the stock is currently owned by company insiders.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.